title: Loss of responsiveness to IGF-I in cells with reduced cathepsin L expression levels.
abstract: The lysosomal cysteine proteinase cathepsin L is involved in proteolytic processing of internalized proteins. In transformed cells, where it is frequently overexpressed, its intracellular localization and functions can be altered. Previously, we reported that treatment of highly metastatic, murine carcinoma H-59 cells with small molecule cysteine proteinase inhibitors altered the responsiveness of the type I insulin-like growth factor (IGF-I) receptor and consequently reduced cell invasion and metastasis. To assess more specifically the role of cathepsin L in IGF-I-induced signaling and tumorigenicity, we generated H-59 subclones with reduced cathepsin L expression levels. These clonal lines showed an altered responsiveness to IGF-I in vitro, as evidenced by (i) loss of IGF-I-induced receptor phosphorylation and Shc recruitment, (ii) reduced IGF-I (but not IGF-II)-induced cellular proliferation and migration, (iii) decreased anchorage-independent growth and (iv) reduced plasma membrane levels of IGF-IR. These changes resulted in increased apoptosis in vivo and an impaired ability of the cells to form liver metastases. The results demonstrate that cathepsin L expression levels regulate cell responsiveness to IGF-I and thereby identify a novel function for cathepsin L in the control of the tumorigenic/metastatic phenotype.
authors.affiliation: Department of Surgery, McGill University, Montreal, Quebec, Canada.
authors.forename: R
authors.initials: R
authors.lastname: Navab
authors.forename: C
authors.initials: C
authors.lastname: Pedraza
authors.forename: L
authors.initials: L
authors.lastname: Fallavollita
authors.forename: N
authors.initials: N
authors.lastname: Wang
authors.forename: E
authors.initials: E
authors.lastname: Chevet
authors.forename: P
authors.initials: P
authors.lastname: Auguste
authors.forename: S
authors.initials: S
authors.lastname: Jenna
authors.forename: Z
authors.initials: Z
authors.lastname: You
authors.forename: A
authors.initials: A
authors.lastname: Bikfalvi
authors.forename: J
authors.initials: J
authors.lastname: Hu
authors.forename: R
authors.initials: R
authors.lastname: O'Connor
authors.forename: A
authors.initials: A
authors.lastname: Erickson
authors.forename: J S
authors.initials: JS
authors.lastname: Mort
authors.forename: P
authors.initials: P
authors.lastname: Brodt
mesh_terms: D000818:Animals; D002277:Carcinoma / Q000378:metabolism / Q000473:pathology*; D056668:Cathepsin L; D002403:Cathepsins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D002448:Cell Adhesion / Q000187:drug effects; D003546:Cysteine Endopeptidases / Q000378:metabolism*; D015536:Down-Regulation; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000378:metabolism / Q000517:prevention & control* / Q000556:secondary*; D008175:Lung Neoplasms / Q000378:metabolism / Q000473:pathology*; D051379:Mice; D008954:Models, Biological; D009361:Neoplasm Invasiveness; D009368:Neoplasm Transplantation; D034741:RNA, Small Interfering / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D034741:RNA, Small Interfering; D007334:Insulin-Like Growth Factor I; D002403:Cathepsins; D003546:Cysteine Endopeptidases; D056668:Cathepsin L; C534278:Ctsl protein, mouse